To assess in vivo efficacy and safety in a high-mortality acute hyperinflammation state, we tested 4] whether anti-DEspR antibody treatment improves median survival in an LPS-induced encephalopathy model in hypertensive rats, and 5] whether concomitant brain target engagement and bioeffects of anti-DEspR on secondary brain injury support in vivo observations. The gene discussed is FBXW7-AS1; the disease is Encephalopathy.